An observational study to describe treatment patterns of patients with BRAFV600E mutant metastatic non-small cell lung cancer (OCTOPUS).

Non-small cell lung cancer (NSCLC) accounts for 80% to 85% of all lung cancer diagnoses. Approximately 1-2% of patients affected by a NSCLC have a specific genetic mutation called BRAFV600E mutation.
In a context of a lack of information, it would be useful for the future patients to provide an overview of diagnosis and treatment processes using data of patients already affected by this cancer.
Therefore, the purpose of this study is to identify treatment patterns given to patients with mutated BRAFV600E mNSCLC and to describe the efficacy of treatments and patients’ quality of life in routine practice.